The use of fibroblast growth factor 23 testing in patients with kidney disease.
about
Phosphate binders in chronic kidney disease: a systematic review of recent data.Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels.FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts.A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum.FGF-23 serum levels and bone histomorphometric results in adult patients with chronic kidney disease on dialysisEffects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients.Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative reviewEmerging drugs for secondary hyperparathyroidism.The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder.Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis.Interorgan handling of fibroblast growth factor-23 in humans.Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis.Association between circulating fibroblast growth factor-23 and age-related cardiovascular-renal parameters in a healthy Chinese population.Progression of Tubulointerstitial Fibrosis and the Chronic Kidney Disease Phenotype - Role of Risk Factors and Epigenetics.The association of the Klotho polymorphism rs9536314 with parameters of calcium-phosphate metabolism in patients on long-term hemodialysis.Mineral adaptations following kidney transplantation.Total Phosphate Elimination is Negatively Associated With Increased Serum Fibroblast Growth Factor 23 Levels in Patients who Undergo Peritoneal Dialysis.Is there a role for newer biomarkers in chronic kidney disease-mineral and bone disorder management?Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease.
P2860
Q31039292-B2C894EB-6B87-40FA-B664-11FE7D921AD4Q33611054-640D3C88-4E99-4178-9693-AD5D4E9E786EQ33793927-8F253EAC-2F58-4EC8-B7E4-FC7A1C5F4CF6Q33916132-560B2777-E5C2-44E9-BCA5-B7DC9D694621Q35949319-E92C2783-7D5F-46D7-9E81-11355FB5484FQ36194460-85DBCAA3-DEEA-4C8D-A4CC-2A3657EAA5E5Q36423189-18BDC009-C20B-4115-A7AB-D5E96DE6D830Q37695914-96C48BC7-1189-419C-AF45-41B62E9DACF7Q38363615-969CA6B6-61A6-482E-B93E-6A62EC79D1F8Q38584122-EAB9DD7B-FE21-42F6-B8FA-3D587B80D1B8Q39056902-70C7D492-2A3D-4F33-965E-42AE77EE4D5AQ39456034-BAE64BA0-78E4-4E49-B402-D7146E979AE3Q40279706-2AB6F303-CFB2-4838-A818-CFABEE3174FBQ40646761-15C5035D-0ECE-4A7C-8645-E07A7A44C73FQ41333737-D490D713-0E11-4E56-9E1A-C538F45F911CQ50672266-3492B01A-0793-4D23-896C-224025598525Q50933711-0E40702E-AB0C-4D2D-9314-6039BC4D3AC2Q51197552-40AC014E-AC74-4160-9394-25873AC604AAQ53342879-605C8EA3-9847-4BAD-A6DF-4BF1A9358637Q55442487-8171F5D5-CD81-4831-A650-5C129D2D011A
P2860
The use of fibroblast growth factor 23 testing in patients with kidney disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The use of fibroblast growth factor 23 testing in patients with kidney disease.
@ast
The use of fibroblast growth factor 23 testing in patients with kidney disease.
@en
type
label
The use of fibroblast growth factor 23 testing in patients with kidney disease.
@ast
The use of fibroblast growth factor 23 testing in patients with kidney disease.
@en
prefLabel
The use of fibroblast growth factor 23 testing in patients with kidney disease.
@ast
The use of fibroblast growth factor 23 testing in patients with kidney disease.
@en
P2860
P356
P1476
The use of fibroblast growth factor 23 testing in patients with kidney disease.
@en
P2093
Edward R Smith
P2860
P304
P356
10.2215/CJN.10941013
P577
2014-02-27T00:00:00Z